Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-04-24
2007-04-24
Bernhardt, Emily (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S255010, C514S254010, C514S218000, C540S575000, C544S360000, C544S364000, C544S371000, C544S372000, C544S376000, C544S377000, C544S387000, C544S388000, C544S390000, C544S391000
Reexamination Certificate
active
10185861
ABSTRACT:
A novel class of substituted piperazines and diazepanes, pharmaceutical compositions comprising them and use thereof in the treatment of diseases and disorders related to the histamine H3 receptor. More particularly, the compounds are useful for the treatment of diseases and disorders in which an interaction with the histamine H3 receptor is beneficial.
REFERENCES:
patent: 2724713 (1955-11-01), Goldman et al.
patent: 3957779 (1976-05-01), Seng et al.
patent: 4241062 (1980-12-01), Hannah
patent: 4308382 (1981-12-01), Zenitz
patent: 4474783 (1984-10-01), Robba et al.
patent: 5756730 (1998-05-01), Terada et al.
patent: 6316475 (2001-11-01), Bennani et al.
patent: 6723730 (2004-04-01), Bakthavatchalam et al.
patent: 2 141 634 (1972-02-01), None
patent: 2 360 362 (1974-06-01), None
patent: 2304155 (1974-08-01), None
patent: 19621221 (1997-11-01), None
patent: 0203743 (1991-02-01), None
patent: 0978512 (2000-02-01), None
patent: 57-7459 (1982-01-01), None
patent: WO 81/02421 (1981-09-01), None
patent: WO 92/02498 (1992-02-01), None
patent: WO 95/00512 (1995-05-01), None
patent: WO 97/17345 (1997-05-01), None
patent: WO 99/42458 (1999-08-01), None
patent: WO 00/51984 (2000-09-01), None
patent: WO 00/76970 (2000-12-01), None
patent: WO 01/44191 (2001-06-01), None
patent: WO 01/66534 (2001-09-01), None
patent: WO 01/74773 (2001-10-01), None
patent: WO 01/74810 (2001-10-01), None
patent: WO 01/74813 (2001-10-01), None
patent: WO 01/74814 (2001-10-01), None
patent: WO 01/74815 (2001-10-01), None
patent: WO 02/012190 (2002-02-01), None
Phillips et al. Annual Reports in medicinal Chemistry, vol. 33, p. 31-40 (1998).
Passani et al. Neuroscience and Biobehavioral Reviews, vol. 24, p. 107-113 (2000).
Leurs et al. TIPS, vol. 19, p. 177-183 (1998).
Kyoto Pharamaceutical, Chemical Abstract, vol. 96, No. 217485, (1982) Abstract for JP 57007459 (Jan. 14, 1982).
Mignot et al. Nature Neuroscience Supplement, vol. 5, p. 1071-1075 (2002).
Tozer et al., Ashley Publications Ltd., pp. 1045-1055 (2000).
Walczynski et al., Arch. Pharm. Pharm. Med. Chem., pp. 389-398 (1999).
Linney et al., J. Med. Chem., vol. 43, pp. 2362-2370 (2000).
Ganellin et al., Arch. Pharm. Pharm. Med. Chem., pp. 395-404 (1998).
Walczynski et al., Elsevier Science S.A., vol. 54, pp. 684-694 (1999).
Nishi et al., Chem. Pharm. Bull., vol. 31, pp. 852-860 (1983).
Dauzonne et al. Eur. J. Med. Chem., vol. 30, pp. 53-59 (1995).
Vejdelek et al., Collection Czechoslovak Chem. Commun., vol. 48, pp. 2977-2988 (1983).
Valenta et al., Collect. Czech. Chem. Commun., vol. 55, pp. 1613-1629 (1990).
Stark et al., Drugs of the Future, vol. 21, No. 5, pp. 507-520 (1996).
Leurs et al., Progress in Drug Research, vol. 45, pp. 107-165 (1995).
Lovenberg et al., Molecular Pharmacology, vol. 55, pp. 1101-1107 (1999).
Morisset et al., Letters to Nature, vol. 408, pp. 860-864 (2000).
Tiwari et al., Drug Design and Discovery, vol. 12, pp. 249-258 (1995).
Brown et al., J. Am. Chem. Soc., vol. 119, pp. 3288-3295 (1997).
Gayral et al., Arzneim.-Forsch./Drug Res. vol. 45 (II), No. 10, pp. 1122-1127 (1995).
Abstract CA 59:13982a (2002), Christensen et al.
Abstract JP Patent No. JP 57175168 A2.
Abstract JP Patent No. JP 57002274 A2.
Baba et al., J. Med. Chem., vol. 21, No. 6, pp. 525-529 (1978).
Dahlbom et al., Acta Chem Scand., vol. 15, No. 6, pp. 1367-1371 (1961).
Harfenist, J. Am. Chem. Soc., vol. 76, pp. 4991-4993 (1954).
Mndzhoyan et al., Chemical Abstracts, vol. 70, No. 21 (1969).
Petigara et al., J. Med. Chem., American Chemical Society, vol. 11, pp. 332-336 (1968).
Zlatoidsky et al. Eur. J. Med. Chem., vol. 31, No. 11, pp. 895-899 (1996).
Andersen Knud Erik
Dorwald Florencio Zaragoza
Sørensen Jan Lindy
Bernhardt Emily
Bork Richard W.
Green Reza
Novo Nordisk A S
Wilk-Orescan Rosemarie
LandOfFree
Substituted piperazines and diazepanes does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Substituted piperazines and diazepanes, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Substituted piperazines and diazepanes will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3730552